Comprehensive Stock Comparison
Compare Celldex Therapeutics, Inc. (CLDX) vs Recursion Pharmaceuticals, Inc. (RXRX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | RXRX | 26.9% revenue growth vs CLDX's -78.6% |
| Quality / Margins | RXRX | -8.6% net margin vs CLDX's -172.5% |
| Stability / Safety | CLDX | Beta 1.14 vs RXRX's 2.38, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CLDX | +46.3% vs RXRX's -51.1% |
| Efficiency (ROA) | RXRX | -43.7% ROA vs CLDX's -44.4%, ROIC -95.8% vs -35.2% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibody therapies for cancer and inflammatory diseases. It generates revenue primarily through research collaborations and licensing agreements — with future income dependent on successful clinical development and commercialization of its pipeline candidates. The company's competitive advantage lies in its proprietary antibody platform technology and focused expertise in developing monoclonal and bispecific antibodies against validated targets.
Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses an industrialized, technology-driven platform to discover and develop new drugs. It generates revenue primarily through research collaborations and partnerships with pharmaceutical companies — like its major deal with Bayer — while advancing its own pipeline of drug candidates. Its key competitive advantage is its proprietary platform that combines automation, artificial intelligence, and massive biological datasets to systematically decode biology and accelerate drug discovery at scale.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CLDX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). RXRX leads in 2 (Financial Metrics, Valuation Metrics).
Financial Metrics (TTM)
RXRX is the larger business by revenue, generating $75M annually — 49.7x CLDX's $2M. RXRX is the more profitable business, keeping -8.6% of every revenue dollar as net income compared to CLDX's -172.5%. On growth, RXRX holds the edge at +6.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CLDXCelldex Therapeut… | RXRXRecursion Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $75M |
| EBITDAEarnings before interest/tax | -$284M | -$564M |
| Net IncomeAfter-tax profit | -$259M | -$645M |
| Free Cash FlowCash after capex | -$213M | -$378M |
| Gross MarginGross profit ÷ Revenue | +100.0% | -32.1% |
| Operating MarginEBIT ÷ Revenue | -191.6% | -8.7% |
| Net MarginNet income ÷ Revenue | -172.5% | -8.6% |
| FCF MarginFCF ÷ Revenue | -142.2% | -5.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -93.6% | +6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -73.2% | +60.4% |
Valuation Metrics
| Metric | CLDXCelldex Therapeut… | RXRXRecursion Pharmac… |
|---|---|---|
| Market CapShares × price | $2.0B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $2.0B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -7.72x | -2.55x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1334.98x | 25.96x |
| Price / BookPrice ÷ Book value/share | 3.80x | 1.45x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CLDX delivers a -49.1% return on equity — every $100 of shareholder capital generates $-49 in annual profit, vs $-57 for RXRX. CLDX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RXRX's 0.07x. On the Piotroski fundamental quality scale (0–9), RXRX scores 4/9 vs CLDX's 3/9, reflecting mixed financial health.
| Metric | CLDXCelldex Therapeut… | RXRXRecursion Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -49.1% | -57.0% |
| ROA (TTM)Return on assets | -44.4% | -43.7% |
| ROICReturn on invested capital | -35.2% | -95.8% |
| ROCEReturn on capital employed | -44.7% | -50.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.07x |
| Net DebtTotal debt minus cash | -$27M | -$665M |
| Cash & Equiv.Liquid assets | $29M | $743M |
| Total DebtShort + long-term debt | $2M | $78M |
| Interest CoverageEBIT ÷ Interest expense | — | -491.16x |
Total Returns (with DRIP)
A $10,000 investment in CLDX five years ago would be worth $10,674 today (with dividends reinvested), compared to $2,039 for RXRX. Over the past 12 months, CLDX leads with a +46.3% total return vs RXRX's -51.1%. The 3-year compound annual growth rate (CAGR) favors CLDX at -11.1% vs RXRX's -23.4% — a key indicator of consistent wealth creation.
| Metric | CLDXCelldex Therapeut… | RXRXRecursion Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +11.4% | -12.6% |
| 1-Year ReturnPast 12 months | +46.3% | -51.1% |
| 3-Year ReturnCumulative with dividends | -29.7% | -55.0% |
| 5-Year ReturnCumulative with dividends | +6.7% | -79.6% |
| 10-Year ReturnCumulative with dividends | -70.5% | -79.6% |
| CAGR (3Y)Annualised 3-year return | -11.1% | -23.4% |
Risk & Volatility
CLDX is the less volatile stock with a 1.14 beta — it tends to amplify market swings less than RXRX's 2.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLDX currently trades 96.2% from its 52-week high vs RXRX's 46.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CLDXCelldex Therapeut… | RXRXRecursion Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 2.38x |
| 52-Week HighHighest price in past year | $31.29 | $7.89 |
| 52-Week LowLowest price in past year | $14.40 | $2.98 |
| % of 52W HighCurrent price vs 52-week peak | +96.2% | +46.5% |
| RSI (14)Momentum oscillator 0–100 | 71.7 | 46.7 |
| Avg Volume (50D)Average daily shares traded | 547K | 18.2M |
Analyst Outlook
Wall Street rates CLDX as "Buy" and RXRX as "Hold". Consensus price targets imply 199.7% upside for RXRX (target: $11) vs -20.2% for CLDX (target: $24).
| Metric | CLDXCelldex Therapeut… | RXRXRecursion Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $24.00 | $11.00 |
| # AnalystsCovering analysts | 19 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | May 21 | Feb 26 | Change |
|---|---|---|---|
| Celldex Therapeutic… (CLDX) | 100 | 80.54 | -19.5% |
| Recursion Pharmaceu… (RXRX) | 183.44 | 23.22 | -87.3% |
Celldex Therapeutic… (CLDX) returned +7% over 5 years vs Recursion Pharmaceu… (RXRX)'s -80%. A $10,000 investment in CLDX 5 years ago would be worth $10,674 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Celldex Therapeutic… (CLDX) | $7M | $2M | -77.9% |
| Recursion Pharmaceu… (RXRX) | $2M | $75M | +4264.8% |
Celldex Therapeutics, Inc.'s revenue grew from $7M (2016) to $2M (2025) — a -15.4% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Celldex Therapeutic… (CLDX) | -18.9% | -172.5% | -810.9% |
| Recursion Pharmaceu… (RXRX) | -36.5% | -8.6% | +76.4% |
Celldex Therapeutics, Inc.'s net margin went from -19% (2016) to -173% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Celldex Therapeutic… (CLDX) | -18.99 | -3.9 | +79.5% |
| Recursion Pharmaceu… (RXRX) | -0.37 | -1.44 | -285.9% |
Celldex Therapeutics, Inc.'s EPS grew from $-18.99 (2016) to $-3.90 (2025).
Chart 5Free Cash Flow — 5 Years
Celldex Therapeutics, Inc. generated $-211M FCF in 2025 (-239% vs 2021). Recursion Pharmaceuticals, Inc. generated $-378M FCF in 2025 (-91% vs 2021).
CLDX vs RXRX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is CLDX or RXRX a better buy right now?
Analysts rate Celldex Therapeutics, Inc. (CLDX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CLDX or RXRX?
Over the past 5 years, Celldex Therapeutics, Inc. (CLDX) delivered a total return of +6.7%, compared to -79.6% for Recursion Pharmaceuticals, Inc. (RXRX). A $10,000 investment in CLDX five years ago would be worth approximately $11K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CLDX returned -70.5% versus RXRX's -79.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CLDX or RXRX?
By beta (market sensitivity over 5 years), Celldex Therapeutics, Inc. (CLDX) is the lower-risk stock at 1.14β versus Recursion Pharmaceuticals, Inc.'s 2.38β — meaning RXRX is approximately 109% more volatile than CLDX relative to the S&P 500. On balance sheet safety, Celldex Therapeutics, Inc. (CLDX) carries a lower debt/equity ratio of 0% versus 7% for Recursion Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — CLDX or RXRX?
Recursion Pharmaceuticals, Inc. (RXRX) is the more profitable company, earning -863.4% net margin versus -172.5% for Celldex Therapeutics, Inc. — meaning it keeps -863.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RXRX leads at -867.9% versus -191.6% for CLDX. At the gross margin level — before operating expenses — CLDX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — CLDX or RXRX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is CLDX or RXRX better for a retirement portfolio?
For long-horizon retirement investors, Celldex Therapeutics, Inc. (CLDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.14)). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2.38 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLDX: -70.5%, RXRX: -79.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between CLDX and RXRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.